5-ethyl-8-oxo-[1,3]dioxolo[4,5-g]quinoline-7-carboxylic acid;[(3R,4S,5R,6R)-5-hydroxy-6-[4-hydroxy-3-[[4-hydroxy-3-(3-methylbut-2-enyl)benzoyl]amino]-8-methyl-2-oxochromen-7-yl]oxy-3-methoxy-2,2-dimethyloxan-4-yl] carbamate | 361443-01-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: 5-ethyl-8-oxo-[1,3]dioxolo[4,5-g]quinoline-7-carboxylic acid;[(3R,4S,5R,6R)-5-hydroxy-6-[4-hydroxy-3-[[4-hydroxy-3-(3-methylbut-2-enyl)benzoyl]amino]-8-methyl-2-oxochromen-7-yl]oxy-3-methoxy-2,2-dimethyloxan-4-yl] carbamate
• CAS: 361443-01-8
• 化学式: C44H47N3O16
• 分子量: 873.9
• InChiKey: YJTKNOFVPDGEGY-RNROJPEYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.08
• 重原子数：
  63
• 可旋转键数：
  11
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.34
• 拓扑面积：
  272
• 氢给体数：
  6
• 氢受体数：
  17

文献信息

• Control of aberrant expression vector accumulation during fermentation procedures
  申请人：ELI LILLY AND COMPANY

  公开号：EP0405858A2

  公开（公告）日：1991-01-02

  The present invention provides a method for preventing the accumulation of aberrant expression vectors during fermentation processes which rely on the expression of an expression vector coded gene for production of a polypeptide product of interest. Antibiotics are added at approximately the time at which product expression begins.

  本发明提供了一种在发酵过程中防止异常表达载体积累的方法，发酵过程依赖于表达载体编码基因来生产相关的多肽产品。大约在产品开始表达时加入抗生素。
• US5824496A
  申请人：——

  公开号：US5824496A

  公开（公告）日：1998-10-20